Pharmaceutical Contract Development, Manufacturing, and Services: A Market Poised for Unprecedented Growth

Wednesday, March 19, 2025

The pharmaceutical contract development, manufacturing, and services market is experiencing a period of remarkable growth and transformation. As pharmaceutical companies increasingly seek to streamline their operations, reduce costs, and focus on core competencies, the demand for outsourced services has skyrocketed. This trend, coupled with technological advancements and evolving regulatory landscapes, is reshaping the industry and creating new opportunities for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs).

The global pharmaceutical contract manufacturing and research services market, valued at USD 226.6 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 7.10% from 2023 to 2030.¹ This growth is driven by the cost-saving and time-saving benefi ts associated with outsourcing, as well as the increasing complexity of pharmaceutical formulations. Market participants are continually investing in infrastructure, personnel, and technology to gain a greater share of the outsourcing revenue, leading to a highly competitive and dynamic landscape.

One of the key factors driving the growth of the pharmaceutical contract development and manufacturing market is the rising demand for generics and increased pharmaceutical R&D spending. According to a report by Research Nester, in 2023, more than 5,500 pharmaceutical businesses had active R&D pipelines.² This surge in research and development activities has created a significant opportunity for CDMOs to provide specialized services and support throughout the drug development process.

The market is also witnessing a shift towards biologics and specialty medicines. The growing demand for biological therapies, coupled with advancements in cell and gene therapies, is expected to further propel the growth of the pharmaceutical contract manufacturing and research services market in the coming years.² This trend is particularly evident in the biopharmaceuticals segment, which requires specialized manufacturing processes and advanced facilities.

Technological advancements are playing a crucial role in shaping the future of pharmaceutical manufacturing. The industry is witnessing a rapid adoption of digitalization and automation technologies, which are streamlining manufacturing processes, improving productivity, and ensuring regulatory compliance. Artificial intelligence (AI) and the Internet of Things (IoT) are enabling real-time monitoring and predictive maintenance, minimizing downtime and optimizing resource utilization.⁴

Another significant technological trend is the emergence of advanced analytics and predictive modeling. Pharmaceutical manufacturers are increasingly relying on these tools to optimize production processes, forecast demand, and prevent quality issues. These data-driven approaches enable proactive decision-making, leading to improved efficiency and cost savings.⁴

The concept of on-demand manufacturing is gaining traction in the pharmaceutical industry, enabled by technologies such as 3D printing and continuous manufacturing. This approach allows for flexible and responsive production, reducing the need for extensive inventories and enabling faster response to market demands and supply chain disruptions.⁴ As the industry continues to evolve, these innovative manufacturing methods are likely to become more prevalent, offering new opportunities for CDMOs to differentiate their services.

The market is also witnessing a growing trend towards collaboration and outsourcing. Pharmaceutical manufacturers are increasingly partnering with CDMOs to access specialized expertise, technologies, and production capacity. This trend allows companies to focus on their core competencies, accelerate time to market, and mitigate risks associated with capital-intensive manufacturing investments.⁴

In terms of market segmentation, the pharmaceutical manufacturing services segment is expected to account for the largest share (75.6%) of the pharmaceutical contract development and manufacturing market in 2024.⁵ This dominance can be attributed to the complex requirements of the manufacturing process and the high costs associated with drug manufacturing. Small and medium-sized pharmaceutical companies, in particular, are driving the demand for outsourced manufacturing services as they often lack the necessary infrastructure and technical expertise to handle production in-house.

The global pharmaceutical manufacturing market size, valued at USD 589.06 billion in 2024, is projected to reach USD 1203.95 billion by 2033, growing at a CAGR of 7.41% during the forecast period (2025-2033).⁶ This growth is driven by the increasing demand for pharmaceutical drugs to prevent, treat, and manage diseases and medical conditions. The market encompasses various segments, including prescription, over-the-counter (OTC), generic, and biopharmaceuticals, covering a wide range of therapeutic areas.

Geographically, North America currently dominates the pharmaceutical contract manufacturing market, accounting for 41% of the growth.⁷ However, the Asia Pacific region is expected to witness the highest CAGR (14.2%) during the forecast period.⁹ This rapid growth in the Asia Pacific market can be attributed to the presence of a large and growing patient population, increasing demand for innovative therapies, and the emergence of small and mid-sized pharmaceutical companies in the region.

The regulatory landscape continues to play a crucial role in shaping the pharmaceutical contract development and manufacturing market. Stringent regulatory requirements and the need to comply with Good Manufacturing Practices (GMP) are driving pharmaceutical companies to collaborate with experienced contract manufacturers.³ This trend is particularly evident in the production of highly potent active pharmaceutical ingredients (HPAPIs) and other specialized drug formulations.

One of the most significant regulatory developments in recent years has been the increased focus on quality control and assurance. Regulatory bodies, such as the FDA, are placing greater emphasis on Current Good Manufacturing Practice (CGMP) and the implementation of corrective and preventative action (CAPA) systems.² This heightened scrutiny has led to a greater demand for CDMOs with proven track records of regulatory compliance and quality management.

The COVID-19 pandemic has had a profound impact on the pharmaceutical contract development and manufacturing market. While the pandemic initially disrupted supply chains and temporarily affected market growth, it has also accelerated certain trends within the industry. The urgent need for vaccine development and production has highlighted the importance of flexible and responsive manufacturing capabilities, further driving the demand for CDMO services.

Looking ahead, the pharmaceutical contract development and manufacturing market is poised for continued growth and innovation. The increasing complexity of drug formulations, coupled with the rise of personalized medicine, is creating new opportunities for specialized manufacturing services. CDMOs that can offer end-to-end solutions, from early-stage development to commercial production, are likely to be in high demand.

The adoption of breakthrough technologies, such as continuous manufacturing and single-use systems, is expected to revolutionize pharmaceutical production processes. These innovations offer numerous advantages, including increased flexibility, reduced contamination risks, and improved cost-efficiency. CDMOs that invest in these innovative technologies will be well-positioned to meet the evolving needs of their pharmaceutical clients.

The market outlook for pharmaceutical contract development and manufacturing services remains highly positive. According to a report by Roots Analysis, the global pharmaceutical contract manufacturing market is anticipated to be worth $140 billion by 2030, growing at a rate of 6.5% during the forecast period of 2022-2030.⁷ This growth is driven by the increasing demand for advanced therapies and biologics, as well as the challenges and resource-intensive nature of establishing independent manufacturing capabilities.

As the industry continues to evolve, several key trends are likely to shape its future. The rise of precision medicine and targeted therapies will drive the need for specialized manufacturing facilities capable of producing small batches of high-value medications.8 Additionally, the growing importance of sustainability in pharmaceutical manufacturing is expected to lead to increased adoption of green chemistry principles and environmentally friendly production processes.

In conclusion, the pharmaceutical contract development, manufacturing, and services market is undergoing a period of unprecedented growth and transformation. Driven by technological advancements, changing market dynamics, and evolving regulatory requirements, the industry is poised for continued expansion in the coming years. As pharmaceutical companies increasingly rely on outsourcing to streamline their operations and access specialized expertise, CDMOs that can offer innovative, flexible, and compliant services will be well-positioned to capitalize on this growing market opportunity. The future of pharmaceutical manufacturing lies in collaboration, technological innovation, and a relentless focus on quality and efficiency.

Citations

About the Author

Mike Auerbach, Group Editor-in-Chief, Pharma Group, American Pharmaceutical Revie

Publication Detail

This article appeared in American Pharmaceutical Review - Innovations at Interphex 2025 Supplement

Pages: 19-21

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!